KR20200132920A - 마이크로-rna 및 비만 - Google Patents

마이크로-rna 및 비만 Download PDF

Info

Publication number
KR20200132920A
KR20200132920A KR1020207029243A KR20207029243A KR20200132920A KR 20200132920 A KR20200132920 A KR 20200132920A KR 1020207029243 A KR1020207029243 A KR 1020207029243A KR 20207029243 A KR20207029243 A KR 20207029243A KR 20200132920 A KR20200132920 A KR 20200132920A
Authority
KR
South Korea
Prior art keywords
leu
ser
pro
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207029243A
Other languages
English (en)
Korean (ko)
Inventor
피에르 파올로 판돌피
리카르도 파넬라
Original Assignee
베스 이스라엘 데코니스 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베스 이스라엘 데코니스 메디칼 센터 filed Critical 베스 이스라엘 데코니스 메디칼 센터
Publication of KR20200132920A publication Critical patent/KR20200132920A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207029243A 2018-03-14 2019-03-14 마이크로-rna 및 비만 Withdrawn KR20200132920A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642934P 2018-03-14 2018-03-14
US62/642,934 2018-03-14
PCT/US2019/022350 WO2019178410A1 (en) 2018-03-14 2019-03-14 Micro-rna and obesity

Publications (1)

Publication Number Publication Date
KR20200132920A true KR20200132920A (ko) 2020-11-25

Family

ID=67908026

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207029243A Withdrawn KR20200132920A (ko) 2018-03-14 2019-03-14 마이크로-rna 및 비만
KR1020207029242A Withdrawn KR20200131287A (ko) 2018-03-14 2019-03-14 마이크로-rna 22의 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207029242A Withdrawn KR20200131287A (ko) 2018-03-14 2019-03-14 마이크로-rna 22의 억제제

Country Status (12)

Country Link
US (2) US11753639B2 (enExample)
EP (2) EP3765619B1 (enExample)
JP (2) JP7318166B2 (enExample)
KR (2) KR20200132920A (enExample)
CN (2) CN111918968B (enExample)
AU (2) AU2019234917B2 (enExample)
BR (2) BR112020018705A2 (enExample)
CA (2) CA3093844A1 (enExample)
ES (1) ES3001019T3 (enExample)
RU (2) RU2020131372A (enExample)
SG (2) SG11202008925VA (enExample)
WO (2) WO2019178411A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111918968B (zh) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
CN110609142A (zh) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 一种检测外周血fto蛋白与自身调控元件结合能力的方法与应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117304258B (zh) * 2022-09-09 2024-09-24 湖南大学 一种多肽的用途
EP4353823A1 (en) * 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
SK17432000A3 (sk) 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
ES2534300T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA2634046A1 (en) * 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
AU2013254923A1 (en) * 2006-04-03 2013-11-28 Santaris Pharma A/S Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
CA3042781C (en) * 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
EP2419537B1 (en) * 2009-04-13 2014-01-29 Somagenics, Inc. Methods and compositions for detection of small rnas
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
TW201238973A (en) * 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
AU2012242761A1 (en) 2011-04-12 2013-10-31 Beth Israel Deaconess Medical Center, Inc. Micro-RNA inhibitors and their uses in disease
US20150031574A1 (en) * 2012-02-23 2015-01-29 Sumitomo Bakelite Co., Ltd. Method for classification of test body fluid sample
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
WO2013181613A1 (en) 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
EP2864482A4 (en) * 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
EP3449001B1 (en) * 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN107432933A (zh) * 2017-07-13 2017-12-05 中南大学湘雅三医院 miR‑22作为靶位点在制备膀胱癌的化疗增敏治疗药物中的应用
WO2019053235A1 (en) * 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
CN111918968B (zh) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
WO2019217907A1 (en) * 2018-05-11 2019-11-14 The Regents Of The University Of California Methods and compositions for the treatment of hepatic and metabolic diseases

Also Published As

Publication number Publication date
AU2019234916B2 (en) 2025-06-26
AU2019234917A1 (en) 2020-10-01
WO2019178410A1 (en) 2019-09-19
EP3765619B1 (en) 2024-10-09
RU2020131372A (ru) 2022-04-14
JP2021518841A (ja) 2021-08-05
EP3765610A1 (en) 2021-01-20
US20210017520A1 (en) 2021-01-21
AU2019234917B2 (en) 2025-06-26
CA3093572A1 (en) 2019-09-19
KR20200131287A (ko) 2020-11-23
WO2019178411A1 (en) 2019-09-19
EP3765610A4 (en) 2022-01-19
BR112020018705A2 (pt) 2021-01-05
CN111918968B (zh) 2023-11-24
BR112020018752A2 (pt) 2021-01-05
EP3765619A4 (en) 2021-12-08
SG11202008921YA (en) 2020-10-29
EP3765619C0 (en) 2024-10-09
SG11202008925VA (en) 2020-10-29
RU2020132725A (ru) 2022-04-15
JP2021518159A (ja) 2021-08-02
CN112119159A (zh) 2020-12-22
US20210017521A1 (en) 2021-01-21
US11753639B2 (en) 2023-09-12
US11499152B2 (en) 2022-11-15
AU2019234916A1 (en) 2020-10-15
JP7318166B2 (ja) 2023-08-01
CN111918968A (zh) 2020-11-10
EP3765619A1 (en) 2021-01-20
ES3001019T3 (es) 2025-03-04
CA3093844A1 (en) 2019-09-19
CN112119159B (zh) 2025-04-29

Similar Documents

Publication Publication Date Title
CN112119159B (zh) micro-RNA和肥胖
CN110382521B (zh) 从氧化应激区分肿瘤抑制性foxo活性的方法
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
RU2742007C2 (ru) Олигонуклеотиды для индуцирования отцовской экспрессии ube3a
CN112220797B (zh) C/EBPα组合物和使用方法
DK2458006T3 (en) Compounds and Methods for Modulating ApoB Expression.
AU2014375206B2 (en) Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
KR102110469B1 (ko) 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
RU2748495C2 (ru) Способы и композиции для модулирования экспрессии аполипопротеина (а)
KR20200140805A (ko) Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
KR20180093977A (ko) 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
TW202536179A (zh) 用於調節ube3a-ats之化合物及方法
TW202605151A (zh) 用於病症及疾病之治療的opa1反義寡聚物
CN115380123A (zh) 基于t细胞受体信号传导基因对前列腺癌对象的放疗反应的预测
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
KR20230074214A (ko) 지방간 질환의 치료 방법
KR20100037637A (ko) Ｅｇｆｒ 억제제 치료에 대한 예측 마커
EP1729930A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
KR20190126812A (ko) 질환 진단용 바이오마커
WO2018209358A2 (en) Systemic delivery of polypeptides
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US20210324478A1 (en) Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid